Evidence map›Paper›PMID 32405350›Full record

ArticleIranian journal of basic medical sciences2020

Possible protective effects of resveratrol in hepatocellular carcinoma.

Seda Cetinkaya Karabekir, Aydan Özgörgülü

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of basic medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Seda Cetinkaya KarabekirUniversity of KTO Karatay, Faculty of Medicine, Department of Histology and Embryology, Konya, Turkey.
Aydan ÖzgörgülüUniversity of Necmettin Erbakan, Faculty of Meram Medicine, Department of Histology and Embryology, Konya, Turkey.
Necmettin Erbakan University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesResveratrol (RSV) is a naturally occurring plant polyphenol with cardioprotective, neuroprotective, immunoregulatory, and anticancer properties and is biologically effective against various diseases. This study aimed to investigate the chemopreventive effect of different doses of RSV against hepatocellular carcinoma (HCC) induced by diethylnitrosamine (DEN) in rats. MATERIALS AND

methodsThe rats were randomly divided into six groups of seven rats each (n=42). The control group (group 1) was injected with saline, group 2 with dimethyl sulfoxide (DMSO), group 3 with DEN, group 4 with DEN and 50 mg/kg of RSV (DEN+RSV 50), group 5 with DEN and 75 mg/kg of RSV (DEN+RSV 75), and group 6 with DEN and 100 mg/kg of RSV (DEN+RSV 100). Pro-apoptotic Bax/anti-apoptotic Bcl-2 and tumor suppressor p53 markers were analyzed by immunostaining.

resultsSuperoxide dismutase, glutathione, and malondialdehyde concentrations were not statistically significant in DEN+RSV 100 group but were closest to the concentrations in control group. Liver function tests showed that enzyme activity (alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and γ-glutamyl transferase) increased in DEN+RSV 50 and DEN+RSV 100 groups compared with control group but decreased in DEN+RSV 50 and DEN+RSV 100 groups compared with DEN group. Bax/Bcl-2 and p53 analysis showed a statistically significant increase in apoptotic cells in DEN+RSV 100 group.

conclusionA 100 mg/kg dose of RSV may be a promising treatment for HCC.

Indexed as

ApoptosisDiethylnitrosamineHepatocellular carcinomaIn vivoResveratrol

Identifiers

PMID32405350
PMCPMC7206832
OpenAlexW2990161763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.